Researchers who studied Medicaid data from Virginia found the number of children under age 18 who were newly treated with a second-generation antipsychotic drug doubled between 2001 and 2005. Data also showed 41.3% of new users had no diagnosis for which treatment was supported by published evidence.

Related Summaries